JP2025060641A5 - - Google Patents

Info

Publication number
JP2025060641A5
JP2025060641A5 JP2024213225A JP2024213225A JP2025060641A5 JP 2025060641 A5 JP2025060641 A5 JP 2025060641A5 JP 2024213225 A JP2024213225 A JP 2024213225A JP 2024213225 A JP2024213225 A JP 2024213225A JP 2025060641 A5 JP2025060641 A5 JP 2025060641A5
Authority
JP
Japan
Prior art keywords
composition
approximately
less
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024213225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025060641A (ja
JP7808674B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/063649 external-priority patent/WO2020113034A1/en
Application filed filed Critical
Publication of JP2025060641A publication Critical patent/JP2025060641A/ja
Publication of JP2025060641A5 publication Critical patent/JP2025060641A5/ja
Application granted granted Critical
Publication of JP7808674B2 publication Critical patent/JP7808674B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024213225A 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用 Active JP7808674B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862773894P 2018-11-30 2018-11-30
US62/773,894 2018-11-30
US201962835242P 2019-04-17 2019-04-17
US62/835,242 2019-04-17
PCT/US2019/063649 WO2020113034A1 (en) 2018-11-30 2019-11-27 Aav viral vectors and uses thereof
JP2021530078A JP7677887B2 (ja) 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021530078A Division JP7677887B2 (ja) 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用

Publications (3)

Publication Number Publication Date
JP2025060641A JP2025060641A (ja) 2025-04-10
JP2025060641A5 true JP2025060641A5 (https=) 2025-10-23
JP7808674B2 JP7808674B2 (ja) 2026-01-29

Family

ID=69167903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530078A Active JP7677887B2 (ja) 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用
JP2024213225A Active JP7808674B2 (ja) 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021530078A Active JP7677887B2 (ja) 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用

Country Status (12)

Country Link
US (1) US20220001028A1 (https=)
EP (1) EP3886919A1 (https=)
JP (2) JP7677887B2 (https=)
KR (1) KR20210099025A (https=)
CN (2) CN120860258A (https=)
AU (1) AU2019389047A1 (https=)
BR (1) BR112021009739A2 (https=)
CA (1) CA3116630A1 (https=)
IL (1) IL282885A (https=)
MX (1) MX2021006359A (https=)
TW (2) TWI897418B (https=)
WO (1) WO2020113034A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3837374A4 (en) * 2018-08-15 2022-06-08 Biogen MA Inc. COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY
TW202140791A (zh) * 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
CN112121179A (zh) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 一种组合物及其在治疗脊髓性肌萎缩症中的应用
US20240084323A1 (en) * 2021-01-13 2024-03-14 Dignity Health Modulation of chitinase protein expression
EP4377459A2 (en) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
EP4380602A4 (en) * 2021-08-03 2025-06-11 The Regents Of The University Of California ADENO-ASSOCIATED VIRAL (AAV)-MEDIATED EXPRESSION OF SPHINGOSINE 1-PHOSPHATE LYASE (SPL) FOR THE TREATMENT OF PULMONARY FIBROSIS
CN114276419B (zh) * 2021-12-30 2023-11-17 上海勉亦生物科技有限公司 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
KR20230152503A (ko) * 2022-04-27 2023-11-03 주식회사 헬릭스미스 척수강 내 투여에 최적화 된 간세포 성장인자 유전자가 도입된 aav 벡터
KR102717399B1 (ko) * 2022-05-10 2024-10-16 서울대학교산학협력단 인간 smn1 단백질 변이체 및 이의 용도
WO2023246734A1 (en) 2022-06-21 2023-12-28 Skyline Therapeutics (Shanghai) Co., Ltd. Recombinant aav for the gene therapy of sma disease
CA3261865A1 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024238958A1 (en) * 2023-05-18 2024-11-21 Ultragenyx Pharmaceutical Inc. Formulations comprising recombinant aav and methods of administering the same
WO2026028089A1 (en) 2024-07-29 2026-02-05 Novartis Ag Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
AU707866B2 (en) 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001514845A (ja) 1997-09-05 2001-09-18 ターゲティッド ジェネティクス コーポレイション 組換えaavベクターの高力価ヘルパーなし調製物を生成するための方法
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
AU2002359284A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN1856576B (zh) * 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
SI2548560T1 (sl) 2005-06-23 2015-12-31 Isis Pharmaceuticals, Inc. Sestavki in postopki za moduliranje izrezovanja smn2
PT3305302T (pt) 2009-06-17 2018-12-14 Biogen Ma Inc Composições e métodos de modulação de excisões de smn2 em um sujeito
DK2529020T3 (en) * 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
AU2013296425B2 (en) * 2012-08-01 2018-06-07 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
MX380973B (es) * 2013-05-01 2025-03-12 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
CN105377039A (zh) * 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
EP4410805A3 (en) * 2014-03-18 2024-11-27 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
MA50016A (fr) * 2017-07-06 2020-07-08 Univ Pennsylvania Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i
MX2020004830A (es) * 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2025060641A5 (https=)
US12409235B2 (en) Gene therapy for AADC deficiency
JP7808674B2 (ja) Aavウイルスベクター及びその使用
JPWO2020113034A5 (https=)
JP2021502123A5 (https=)
Galletta et al. Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy.
CN101084009B (zh) Gh促分泌素及其用途
US20040028736A1 (en) Absorption enhancers
CN115554418A (zh) 一种重组腺相关病毒载体的药物组合物及其用途
WO2025038800A1 (en) Compositions and methods for the treatment of disorders related to frataxin deficiency
JP2025514978A (ja) 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用
AU2003257675A1 (en) Biomolecule transfer method using virus envelope and composition and system therefor
RU2021118669A (ru) Вирусные векторы на основе aav и пути их применения
US20170368006A1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
JP3640980B2 (ja) ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
CN121152634A (zh) 用于治疗恶心和呕吐的方法和用途
JP4629964B2 (ja) ウシの消化器疾患治療剤
JP3034032B2 (ja) 腸疾患用薬剤
Singh et al. Review of therapeutic options for spinal muscular atrophy
Ozawa et al. Renal function in patients with Menkes disease
Intragumtornchai et al. Obstructive uropathy due to extramedullary haematopoiesis in beta thalassaemia/haemoglobin E
JP2022523038A (ja) 遺伝子置換及び抗炎症を介したデュシェンヌ型筋ジストロフィーに対する一段階遺伝子療法
WO2017207600A1 (en) New treatment of sma
JP2003518076A (ja) コスミドdna構築物およびその作製および使用方法
JP2022145646A5 (https=)